ArticleDiscover oncology2026
Identification of DYNLL1 and FGFR2 as potential apoptosis-associated biomarkers in HBV-related hepatocellular carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundHepatitis B virus (HBV) infection is a significant cause of hepatocellular carcinoma (HCC). Dysregulated apoptosis causes tumor formation, progression, and treatment resistance in HBV-related HCC and is involved in its etiology. Nonetheless, the differentially expressed apoptosis-related genes (DEARGs) and underlying molecular mechanisms in HBV-related HCC remain unknown.
methodsIn this study, two gene expression datasets (GSE47197 and GSE112271) of patients with HBV-related HCC were retrieved from public databases. A total of 86 DEARGs were identified via differential expression analysis. Subsequently, a series of bioinformatic analyses were performed on these DEARGs, such as enrichment analyses, random forest survival analysis, hub gene screening, immune infiltration analysis, specific signaling pathways analysis, nomogram model construction, prediction of miRNA and transcription factor (TF), and single cell analysis. Eventually, real-time quantitative polymerase chain reaction (RT-qPCR) was carried out to validate the hub gene expression analysis.
resultsA total of 86 DEARGs were identified in HBV-related HCC, among which two apoptosis-associated hub genes, namely DYNLL1 and FGFR2, were further characterized. Notably, these two genes are closely associated with tumor immune infiltration. In addition, GSVA and GSEA analyses further confirmed that the expression levels of DYNLL1 and FGFR2 directly regulated apoptosis-related signaling pathways, and the calibration curves and nomograms based on these two hub genes showed good performance in prognostic prediction for HBV-related HCC. Moreover, DYNLL1 and FGFR2 genes were found to be enriched in the transcription factor (TF)-binding sites of cisbp_M6134, and single-cell analysis also clarified their expression patterns across various cell types. Finally, RT-qPCR validation results were consistent with our previous differential expression research.
conclusionIn summary, abnormal expression of DYNLL1 and FGFR2 genes in HBV-related HCC is linked to apoptosis and participates in multiple processes of tumor cell biology. DYNLL1 and FGFR2 genes may be promising predictive biomarkers for apoptosis and prognosis of HBV-related HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.